Core Viewpoint - Yuyuan Pharmaceutical plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its competitive edge and international brand image while diversifying its financing channels [1] Summary by Relevant Sections - **Company Strategy** - The company aims to improve its overall competitiveness and international brand image through the planned listing [1] - The move is intended to better utilize international capital markets [1] - **Financial Activities** - The company is actively discussing the issuance of H-shares and the listing process with relevant intermediaries [1] - Specific details regarding the H-share issuance and listing have not yet been finalized [1]

Core Viewpoint - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its competitive edge and international brand image while diversifying its financing channels [1] Group 1 - The third meeting of the company's third board of directors will be held on December 4, 2025, to review the proposal for issuing H-shares [1] - The company aims to utilize international capital markets more effectively through this listing [1] - The move is expected to improve the company's overall competitiveness [1]

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its competitive edge and international brand image while diversifying financing channels [1] Group 1: Company Strategy - The company aims to improve its overall competitiveness and better utilize international capital markets [1] - The issuance of H-shares is part of a strategy to enhance the company's international brand image [1] Group 2: Regulatory Compliance - The company will comply with relevant laws and regulations, including the Company Law, Securities Law, and the Management Measures for the Overseas Issuance of Securities and Listing by Domestic Enterprises [1] - The listing will adhere to the rules of the Hong Kong Stock Exchange [1] Group 3: Shareholder Consideration - The company will consider the interests of existing shareholders when determining the timing and window for the H-share issuance [1] - The decision will be valid for 24 months from the date of the shareholders' meeting resolution, with the possibility of extension [1]

智通财经APP讯，悦康药业(688658.SH)发布公告，为进一步提高公司综合竞争力，提升公司国际品牌 形象，同时更好地利用国际资本市场，多元化融资渠道，公司拟在境外发行股份(H股)并在香港联合交 易所有限公司(简称"香港联交所")主板上市。 ...

Group 1 - The company is in the process of issuing H-shares for overseas listing on the Hong Kong Stock Exchange, targeting qualified overseas investors and certain domestic institutional investors [1] - The final price for the H-share issuance has been set at HKD 116 per share, excluding various transaction fees [2] - The H-shares are expected to be listed and commence trading on December 8, 2025 [3] Group 2 - The company has approved a share repurchase plan using its own funds, with a total repurchase amount between RMB 200 million and RMB 400 million, and a maximum repurchase price of RMB 200 per share [6] - As of November 30, 2025, the company has not yet implemented any share repurchases [8] - The company will adhere to relevant regulations during the repurchase period and will disclose progress in a timely manner [9]

Core Viewpoint - The company is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its international strategy and brand influence [1] Group 1 - The company aims to deepen its international strategic layout and improve its brand's international influence [1] - The company is actively leveraging international capital markets to diversify its financing channels [1] - The H-share listing will not result in changes to the company's controlling shareholder or actual controller [1] Group 2 - The company is currently in discussions with relevant intermediaries regarding the specific progress of the H-share listing [1] - Details of the H-share listing are yet to be determined [1]

格隆汇12月3日丨星宇股份(601799.SH)公布，公司为深化国际化战略布局，提升公司品牌国际影响力， 积极借助国际资本市场拓展多元化融资渠道，助力公司高质量发展，正在筹划发行境外股份(H股)并在 香港联合交易所有限公司(以下简称"香港联交所")上市事宜(以下简称"本次H股上市")。公司正在与相关 中介机构就本次H股上市的具体推进工作进行商讨，相关细节尚未确定，本次H股上市不会导致公司控 股股东和实际控制人发生变化。 ...

Group 1 - The China Securities Regulatory Commission has issued a notice regarding the overseas issuance and listing of Guomin Technology Co., Ltd., allowing the company to issue up to approximately 146 million overseas listed ordinary shares and list on the Hong Kong Stock Exchange [2] - Guomin Technology, established in 2000, is a platform-based integrated circuit design company focused on providing high-security, high-reliability, and highly integrated control chips and system solutions for various smart terminals [2] - The company has a dual business layout, developing both integrated circuits and lithium battery anode materials, positioning itself in the "integrated circuit + new energy materials" sectors [2] Group 2 - According to Zhaoshang Consulting, Guomin Technology ranks among the top five Chinese companies in the global platform-based MCU market by revenue in 2024, and is among the top three in the global 32-bit platform-based MCU market [2] - The company holds the number one position in the Chinese MCU market for built-in commercial password algorithm modules by revenue in 2024, maintaining a leading position in niche markets such as energy storage BMS and smart home control [2]

Core Viewpoint - Nanhua Futures Co., Ltd. is in the process of applying for the issuance of overseas listed shares (H-shares) and listing on the main board of the Hong Kong Stock Exchange, with the application submitted on April 17, 2025, and updated on October 31, 2025 [1][2]. Group 1 - The company has received confirmation from the China Securities Regulatory Commission regarding the filing for the overseas issuance and listing [1]. - The Hong Kong Stock Exchange Listing Committee held a hearing on November 20, 2025, to review the company's application for issuance and listing [2]. - The company has published a post-hearing information set on the Hong Kong Stock Exchange website, which is intended to provide information to the public and qualified investors [2]. Group 2 - The issuance and listing are subject to final approval from relevant regulatory bodies, including the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, indicating uncertainty in the process [3]. - The company will fulfill its information disclosure obligations in accordance with the progress of the matter [3].

Core Viewpoint - Transsion Holdings (688036.SH) has submitted an application for the issuance of overseas listed foreign shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange on December 2, 2025 [1] Group 1 - The application materials were published on the Hong Kong Stock Exchange website on the same day [1] - The application is prepared and published in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1] - The information contained in the application is a draft version and may be updated and revised in due course [1]